Urinary vanin-1 as a novel biomarker for survival in peripheral artery disease

Bernhard Zierfuss ¹, Anna Karlinger ¹, Marija Bojic ^2,3

⁰Medicine II, Division of Angiology, Medical University of Vienna, Vienna, Austria.

Vascular Medicine (London, England) +

|

April 12, 2024

View abstract on PubMed

Summary

Urinary vanin-1 (uVNN1) may help predict mortality risk in patients with peripheral artery disease (PAD). This marker of kidney injury could stratify outcomes for those with PAD and early kidney disease.

Area Of Science

Nephrology
Cardiology
Biomarker Discovery

Background

Chronic kidney disease (CKD) significantly increases morbidity and mortality in peripheral artery disease (PAD) patients.
Currently, no specific functional risk assessment marker for early-stage kidney disease in PAD is established.
Urinary vanin-1 (uVNN1), a marker of oxidative stress and early kidney injury, is proposed as a potential risk stratification tool.

Purpose Of The Study

To investigate the association of urinary vanin-1 (uVNN1) with mortality in patients with peripheral artery disease (PAD).
To evaluate uVNN1 as a potential biomarker for stratifying risk in PAD patients with concurrent kidney disease.

Main Methods

A prospective study of 304 stable PAD patients followed for up to 10 years.
Urinary vanin-1 (uVNN1) levels were measured using ELISA and normalized to urinary creatinine (uVNN1/Cr).
All-cause and cardiovascular mortality were assessed via central death database queries and analyzed using Kaplan-Meier curves and Cox regression.

Main Results

uVNN1/Cr correlated with urine albumin-creatinine ratio (UACR) but not estimated glomerular filtration rate (eGFR).
Higher uVNN1/Cr levels were significantly associated with increased all-cause and cardiovascular mortality.
Multivariable Cox regression confirmed uVNN1/Cr as an independent predictor of mortality in PAD patients.

Conclusions

Urinary vanin-1 (uVNN1) is independently associated with all-cause and cardiovascular mortality in PAD patients.
uVNN1 shows promise as a valuable biomarker for risk stratification in PAD patients, particularly those with early kidney disease.
This finding could lead to improved management strategies for PAD patients with kidney complications.

Keywords:

chronic kidney disease fibrosis inflammation mortality peripheral artery disease (PAD) urinary vanin-1, biomarkers